- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Pointers With Portela: New FDA Treatment for Alopecia Areata
Author(s):
In this week’s Pointers with Dr Portela, the 208SkinDoc talks the newest approval of baricitinib (Olumiant; Eli Lilly and Company) for the treatment of alopecia areata.
Dustin Portela, DO, a board-certified dermatologist and dermatologic surgeon at Treasure Valley Dermatology in Boise, Idaho, talks the FDA approval of baricitinib (Olumiant; Eli Lilly and Company) for the treatment of alopecia areata. He talked about the data and explained the adverse events seen with this treatment.
Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Times®.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Addressing Ongoing Benzoyl Peroxide and Benzene Updates at AAD 2025
Expert Insights Into L'Oréal’s Voluntary Recall of Benzoyl Peroxide Products
Late-Breaking Data: Phase 3 Updates on Ruxolitinib Cream for Prurigo Nodularis
Tattoo Ink Risks, MultiFrax Laser, and the Impact of GLP-1 Medications on Skin Health
How Mindy Haws, MD, Empowers Women in Aesthetic Medicine
LIMITLESS: A Collaborative Effort Between Allergan, The Aesthetic Society, and The American Society of Plastic Surgeons
How the LIMITLESS Initiative Supports Female Leaders in Dermatology
Aesthetic Treatments: More Than Just Enhancements, A Path to Empowerment
Topical Corticosteroids: Potency, Vehicles, and Best Practices
Bunick Highlights Efficacy and Safety of JAK Inhibitors
Related Content
